Hypertension
Conditions
Interventions
Hypertension grade 1 patients in the control group:Take the medication at 7:00 AM (Felodipine 5 mg)
Hypertension grade 1 patients in the experimental group A:For the Shovel-type and Super-shovel-type groups, take the medication at 7:00 AM (Felodipine 5 mg).
For the Non-shovel-type and Reverse-shovel
Hypertension grade 1 patients in the experimental group B:Take the medication at 7:00 PM (Felodipine 5 mg)
Hypertension grade 2 patients in the control group:Take the medication at 7:00 AM (Felodipine 5 mg + Olmesartan 20 mg)
Hypertension grade 2 patients in the experimental group A:For the medication regimen based on different types:
(Scoop type) and (Super scoop type):
Take the medication at 7:00 AM (Felodipine 5 mg +
Hypertension grade 2 patients in the experimental group B:Take the medication at 7:00 PM (Felodipine 5 mg + Olmesartan 20 mg)
Hypertension grade 3 patients in the control group:Take the medication at 7:00 AM (Felodipine 10 mg + Olmesartan 20 mg)
Hypertension grade 3 patients in the experimental group A:For the medication regimen based on different types:
(Scoop type) and (Super scoop type):
Take the medication at 7:00 AM (Felodipine 10 mg +
Hypertension grade 3 patients in the experimental group B:Take the medication at 7:00 PM (Felodipine 10 mg + Olmesartan 20 mg)
Sponsors
First Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Signed and dated informed consent prior to the conduct of the study; 2. >=18-year-old patients with essential hypertension grade 1-3; 3. Not participating in other hypertension studies; 4. The diagnostic criteria for hypertension are based on the Guidelines for the Prevention and Treatment of Hypertension in China (2024 Revised Edition), that is, in the absence of antihypertensive drugs, blood pressure SBP>=140mmHg and/or DBP>=90mmHg should be measured three times on the same day; or 24hBP>=130/80mmHg, dBP>=135/85mmHg, nBP>=120/70mmHg.
Exclusion criteria
Exclusion criteria: 1. Secondary hypertension. 2. Comorbidities requiring medications that affect blood pressure. 3. History of coronary artery disease, myocardial infarction, or stroke within the last 6 months. 4. Atrial fibrillation or other clear arrhythmias. 5. Severe liver dysfunction or renal dysfunction. 6. History of kidney disease or renovascular disease. 7. Pregnant or breastfeeding women, or women planning pregnancy within the next 12 months. 8. Other comorbidities considered unsuitable for participation in the trial, such as thyroid disease, acute infectious diseases, chronic psychiatric disorders, tumors, etc. 9. Any other known factors, diseases, or clinically relevant medical or surgical conditions that may pose a risk to the participant, affect treatment adherence, the progress of the study, or the interpretation of results.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Pressure;Renin;Blood pressure variability; | — |
Countries
China
Contacts
Public ContactZhao Li
First hospital of China medical university
Outcome results
None listed